Download PDF
Semin Neurol 2002; 22(1): 017-026
DOI: 10.1055/s-2002-33045
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Alphabet Soup: A Personal, Evolving, Mostly Evidence-Based and Logical, Sequential Approach to the "ABCNR" Drugs in Multiple Sclerosis

David H. Mattson
  • Professor of Neurology, Director, Neuroimmunology and MS Section, Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana
Further Information

Publication History

Publication Date:
12 August 2002 (online)

    Permissions and Reprints

ABSTRACT

With the development of multiple options for immunotherapy in multiple sclerosis, the clinician is faced with the challenge of keeping pace with the literature, acquiring familiarity with the various treatment options and opinions, and then offering the patients the most current and appropriate management. Given the inherent nature of a multifocal and unpredictable disease such as multiple sclerosis, along with the availability of multiple treatment options, it behooves the clinician to develop an evidence-based rationale for how to best manage patients. This article reflects the common questions that arise from referring neurologists regarding my personal approach to the management of patients with multiple sclerosis.

KEYWORDS

Multiple sclerosis - immunotherapy - demyelinating disease

REFERENCES

  • 1 McFarlin D E, McFarland H F. Multiple sclerosis.  N Engl J Med . 1982;  307 1183-1252
    PubMedGoogle Scholar
  • 2 Rudick R A, Cohen J A, Guttman-Weinstock B. Management of multiple sclerosis.  New Engl J Med . 1997;  337 1604-1611
    CrossrefPubMedGoogle Scholar
  • 3 Goodin D S, Frohman E M, Garmany G P. Disease modifying therapies in multiple sclerosis.  Neurology . 2002;  58 169-178
    CrossrefPubMedGoogle Scholar
  • 4 Lublin F D, Reingold S C. Defining the clinical course of multiple sclerosis: results of an international survey.  Ann Neurol . 1996;  46 907-911
    CrossrefPubMedGoogle Scholar
  • 5 Weinshenker B G, Bass B, Rice G PA. The natural history of multiple sclerosis: a geographic based study. I. Clinical course and disability.  Brain . 1989;  112 133-146
    CrossrefPubMedGoogle Scholar
  • 6 Weinshenker B G, Bass B, Rice G PA. The natural history of multiple sclerosis: a geographically based study. II. Predictive value of the early clinical course.  Brain . 1989;  112 1419-1428
    CrossrefPubMedGoogle Scholar
  • 7 Khoury S J, Guttman C RG, Orav E J. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden.  Neurology . 1994;  44 2120-2124
    PubMedGoogle Scholar
  • 8 Beck R, for the Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the Optic Neuritis Treatment Trial.  Neurology . 1997;  49 1404-1413
    PubMedGoogle Scholar
  • 9 Miller D H, Ormerod I EC, Rudge P, Kendall R E, Moseley I F, McDonald W I. The early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord.  Ann Neurology . 1989;  26 635-639
    PubMedGoogle Scholar
  • 10 Paolino E, Fainardi E, Ruppi P. A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis.  J Neurol Neurosurg Psych . 1996;  60 572-575
    PubMedGoogle Scholar
  • 11 Filippi M, Horsfield M A, Morrissey S P. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis.  Neurology . 1994;  44 635-641
    PubMedGoogle Scholar
  • 12 McDonald W I, Compston A, Edan G. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis.  Ann Neurol . 2001;  50 121-127
    CrossrefPubMedGoogle Scholar
  • 13 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multi-center, randomized, double-blinded, placebo-controlled trial.  Neurology . 1993;  43 665-661
    PubMedGoogle Scholar
  • 14 Lublin F D, Whitaker J N, Eidelman B H, Miller A E, Arnason B GW, Burks J S. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference.  Neurology . 1996;  46 12-18
    PubMedGoogle Scholar
  • 15 Jacobs L D, Cookfair D L, Rudick R A. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.  Ann Neurol . 1996;  39 285-294
    CrossrefPubMedGoogle Scholar
  • 16 The PRISMS study group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS.  Neurology . 2001;  56 1628-1636
    PubMedGoogle Scholar
  • 17 Rice G. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.  Neurology . 2001;  58 1297-1298
    PubMedGoogle Scholar
  • 18 Johnson K P, Brooks B R, Cohen J A. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of phase III multicenter, double-blind, placebo-controlled trial.  Neurology . 1995;  45 1268-1276
    CrossrefPubMedGoogle Scholar
  • 19 Millefiorini E, Gasperini C, Pozzilli C. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.  J Neurol . 1997;  244 153-159
    PubMedGoogle Scholar
  • 20 Jacobs L D, Beck R W, Simon J H. Intramuscular interferon Beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.  NEJM . 2000;  343 898-904
    CrossrefPubMedGoogle Scholar
  • 21 European Study Group on Interferon-beta-1b in secondary progressive MS. Placebo-controlled multicentre randomized trial of interferon B-1b in treatment of secondary progressive multiple sclerosis.  Lancet . 1998;  352 1491-1497
    CrossrefPubMedGoogle Scholar
      >